S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NYSE:CRL - Charles River Laboratories Intl. Stock Price, Forecast & News

$161.05
-1.41 (-0.87 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$159.88
Now: $161.05
$164.86
50-Day Range
$154.57
MA: $162.08
$178.34
52-Week Range
$123.17
Now: $161.05
$179.38
Volume412,900 shs
Average Volume371,203 shs
Market Capitalization$7.89 billion
P/E Ratio31.83
Dividend YieldN/A
Beta1.18
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.62 billion
Cash Flow$10.46 per share
Book Value$33.45 per share

Profitability

Net Income$252.02 million

Miscellaneous

Employees17,100
Market Cap$7.89 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.


Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) announced its earnings results on Tuesday, February, 11th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.83 by $0.18. The medical research company had revenue of $691.10 million for the quarter, compared to analyst estimates of $685.46 million. Charles River Laboratories Intl. had a return on equity of 22.17% and a net margin of 9.61%. Charles River Laboratories Intl.'s quarterly revenue was up 14.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.49 EPS. View Charles River Laboratories Intl.'s Earnings History.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Charles River Laboratories Intl..

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. updated its FY20 earnings guidance on Tuesday, February, 11th. The company provided earnings per share guidance of $7.45-7.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.38. The company issued revenue guidance of +13-14.5% to $2.96-3.00 billion, compared to the consensus revenue estimate of $2.90 billion.

What price target have analysts set for CRL?

16 equities research analysts have issued twelve-month target prices for Charles River Laboratories Intl.'s shares. Their forecasts range from $138.00 to $203.00. On average, they expect Charles River Laboratories Intl.'s share price to reach $171.33 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Charles River Laboratories Intl..

What is the consensus analysts' recommendation for Charles River Laboratories Intl.?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..

Has Charles River Laboratories Intl. been receiving favorable news coverage?

Press coverage about CRL stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Charles River Laboratories Intl. earned a news impact score of -1.2 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Charles River Laboratories Intl..

Are investors shorting Charles River Laboratories Intl.?

Charles River Laboratories Intl. saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 923,300 shares, a decrease of 10.4% from the January 30th total of 1,030,000 shares. Based on an average trading volume of 312,200 shares, the short-interest ratio is presently 3.0 days. Approximately 1.9% of the shares of the stock are sold short. View Charles River Laboratories Intl.'s Current Options Chain.

Who are some of Charles River Laboratories Intl.'s key competitors?

What other stocks do shareholders of Charles River Laboratories Intl. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include Boeing (BA), Mastercard (MA), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), AT&T (T), Verizon Communications (VZ), Adobe (ADBE), Celgene (CELG) and Intuitive Surgical (ISRG).

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the folowing people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
  • Mr. David P. Johst, Corp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer (Age 57)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (3.91%), AQR Capital Management LLC (3.42%), Renaissance Technologies LLC (2.92%), Kayne Anderson Rudnick Investment Management LLC (2.48%), State Street Corp (2.29%) and FIL Ltd (1.75%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

Which institutional investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Acadian Asset Management LLC, Bank of New York Mellon Corp, First Trust Advisors LP, Los Angeles Capital Management & Equity Research Inc., Lord Abbett & CO. LLC, Goldman Sachs Group Inc. and Monarch Partners Asset Management LLC. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David Ross Smith, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

Which institutional investors are buying Charles River Laboratories Intl. stock?

CRL stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Iridian Asset Management LLC CT, Alyeska Investment Group L.P., Point72 Asset Management L.P., Personal Capital Advisors Corp, Kayne Anderson Rudnick Investment Management LLC, Marshall Wace LLP and Thrivent Financial for Lutherans. View Insider Buying and Selling for Charles River Laboratories Intl..

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $161.05.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $7.89 billion and generates $2.62 billion in revenue each year. The medical research company earns $252.02 million in net income (profit) each year or $6.73 on an earnings per share basis. Charles River Laboratories Intl. employs 17,100 workers across the globe.View Additional Information About Charles River Laboratories Intl..

What is Charles River Laboratories Intl.'s official website?

The official website for Charles River Laboratories Intl. is http://www.criver.com/.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories Intl. (NYSE CRL)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  466 (Vote Underperform)
Total Votes:  856
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel